Studies reveal that as people age, their skin progressively becomes less hydrated and weaker, along with turning less stretchy, resulting in the formation of wrinkles. It is reported that most individuals develop wrinkles between the ages of 40 and 50 due to loss of moisture and thickness of the skin. With the expanding aging population (60 years and older), expected to reach 2.1 billion by 2050, the demand for drugs that can prevent and treat wrinkles is likely to grow significantly.
The Wrinkles Drug Pipeline Report by Expert Market Research gives comprehensive insights into drugs currently undergoing wrinkles clinical trials. It covers various aspects related to the details of each of these wrinkles drugs under development. The report includes the analysis of over 100 pipeline drugs and 50+ companies. The wrinkles pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from wrinkles.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing wrinkles pipeline development activities.
Wrinkles refer to a natural part of aging that causes the formation of creases, folds, or ridges in the skin. Sun exposure, smoking, and genetics, among others, also result in the development of wrinkles. These folds or furrows fall into categories: dynamic and static. Dynamic wrinkles occur due to repeated facial movements whereas static wrinkles are caused by loss of elasticity of the skin.
Prescription creams and serums such as retinoids are commonly recommended for wrinkles treatment. Botulinum toxin injections, which temporarily relax muscles, are also used to reduce wrinkles. Injections of fillers such as hyaluronic acid are increasingly to plump up the skin and address wrinkles. With the increasing awareness of skin health and the growing demand for long-lasting and permanent anti-aging solutions, the drug pipeline for wrinkles is poised to expand in the coming years.
This section of the report covers the analysis of wrinkles drug candidates based on several segmentations including:
By Phase
EMR’s pipeline assessment report covers 50+ drug analyses based on phase:
By Drug Class
EMR’s wrinkles therapeutic assessment report covers 50+ drug analyses based on drug classes:
By Route of Administration
EMR’s pipeline assessment report covers 50+ drug analyses based on the route of administration.
The report covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase I covers a major share of the total clinical trials for wrinkles.
The drug molecule categories covered under wrinkles pipeline analysis include monoclonal antibodies, peptides, polymers, small molecules, and gene therapy. The report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for wrinkles.
The EMR wrinkles drug report insights cover the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in wrinkles clinical trials:
This section covers the detailed analysis of each drug under multiple phases including phase I, phase II, phase III, phase IV, and emerging drugs for wrinkles. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of wrinkles drug candidates.
Description 1: Sponsored by AbbVie, this prospective, multi-center, open-label clinical study aims to examine patient natural outcomes and satisfaction post administration of BOTOX® (Botulinum Toxin Type A) purified neurotoxin complex. The Phase IV trial has enrolled an estimated 100 participants with upper facial lines (forehead lines, glabellar lines, and lateral canthal lines).
Description 2: Krystal Biotech, Inc., a gene therapy biotechnology company, is conducting a Phase 3 clinical trial of a replication-incompetent, non-integrating vector expressing human type III collagen (COL3), named KB301, to treat superficial skin depressions. The study has enrolled around 85 patients and is expected to be completed by May 2029.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The Wrinkles Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for wrinkles. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into wrinkles collaborations, regulatory environments, and potential growth opportunities within the treatment landscape.
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
Share